Parkinson's Disease (PD) is a progressive neurodegenerative disorder that predominantly affects the dopaminergic neurons in the substantia nigra, causing motor and non-motor symptoms. The pathogenesis of PD is multifactorial, involving genetic and environmental factors. This complex disorder requires a comprehensive understanding for optimal patient management.
PD affects approximately 1% of individuals over the age of 60, with a higher prevalence in males. Risk factors include age, genetic predisposition, exposure to certain pesticides, and history of head injury. Conversely, caffeine intake and tobacco use appear to have a protective effect.
The hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. This results in an imbalance in the direct and indirect pathways of the basal ganglia, causing motor symptoms. The presence of Lewy bodies, composed of alpha-synuclein, is another characteristic feature.
PD presents with both motor (bradykinesia, rigidity, rest tremor, postural instability) and non-motor symptoms (depression, constipation, sleep disturbances). Diagnosis is primarily clinical, supported by response to dopaminergic therapy. Neuroimaging can aid in differentiating PD from other parkinsonian syndromes.
Treatment of PD is symptomatic, with levodopa being the most effective medication for motor symptoms. Non-motor symptoms are managed with a multidisciplinary approach. Deep brain stimulation can be considered in patients with motor complications not adequately controlled by medication.
PD is a complex neurodegenerative disorder with a multifactorial pathogenesis. A comprehensive understanding of its epidemiology, pathophysiology, clinical presentation, and treatment options is essential for healthcare professionals to provide optimal patient care.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation